Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$327.54K
16.23K shares · 0.0% of portfolio
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Rancho Cucamonga, United States and has 1,976 employees. The company is worth $1.11B and trades at 15.5x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $719.89M in fiscal 2025, down 1.7% from the year before. Net income was $98.09M. The share price is 11.8% below its 52-week high of $29.52. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $10.6M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +32.3% over 5Y.
today you would have $1,384.90▲ +38.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $26.78 | $37.13 | $61.85 | $28.02 | $23.29 | $20.11 | $19.29 | $19.90 | $19.24 | $18.42 | $14.23 | $11.61 | |
| P/E | 18.6x | 13.2x | 12.1x | 23.8x | 16.1x | 18.6x | 670.3x | 19.7x | — | 240.5x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 18.6 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BCAXBicara Therapeutics Inc. | $16.78 | — | 2.4x | 0.00% | -41.01% | $1.11B |
| IRMDIradimed Corp | $87.64 | 49.0x | 11.0x | 1.45% | 23.52% | $1.12B |
| CTYCity Therapeutics Inc | $22.40 | — | — | — | — | $1.13B |
| STAAStaar Surgical Co | $22.49 |
| 87.7x |
| — |
| — |
| P/S | 2.7x | 1.7x | 2.4x | 4.6x | 2.7x | 2.6x | 2.7x | 2.8x | 3.2x | 3.7x | 3.3x | 2.5x | 2.5x |
| P/B | 2.5x | 1.5x | 2.4x | 4.7x | 2.5x | 2.5x | 2.4x | 2.3x | 2.8x | 2.7x | 2.6x | 2.2x | 1.8x |
| EPS | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | -$0.12 | $0.08 | $0.21 | -$0.06 | -$0.25 |
| Profit margin | 8.74% | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% | 0.40% | 15.18% | -1.95% | 1.52% | 3.85% | -1.11% | -5.08% |
| ROE | 7.71% | 12.44% | 21.78% | 21.51% | 17.29% | 13.94% | 0.35% | 12.83% | -1.73% | 1.09% | 2.98% | -0.94% | -3.80% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
+104.6% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 281.1x |
| 3.1x |
| 0.00% |
| 1.09% |
| $1.13B |
| IAMIambic Therapeutics, Inc. | $23.81 | — | — | 0.00% | — | $1.13B |
| REPLReplimune Group, Inc. | $11.99 | — | 9.5x | 0.00% | -134.29% | $1.13B |